Concord Drugs Ltd

Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 May 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 04 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to an attractive territory, driven by evolving price-to-earnings and price-to-book value metrics. This transition comes alongside robust stock performance that has significantly outpaced the Sensex over the past year, signalling renewed investor interest in this micro-cap pharmaceutical player.

Concord Drugs Ltd has demonstrated a marked improvement in its financial performance for the quarter ended March 2026, signalling a significant turnaround from previous periods. The company’s revenue, profitability, and earnings per share have all reached their highest quarterly levels in recent history, reflecting a very positive shift in its financial trend and investor sentiment.

Concord Drugs Limited, a Telangana-based pharmaceutical manufacturer specialising in finished formulations and injectables, reported a dramatic surge in quarterly revenues for Q4 FY26, with net sales soaring 264.77% year-on-year to ₹37.90 crores. Net profit jumped to ₹0.53 crores from ₹0.04 crores in the year-ago quarter, marking a 1,225.00% YoY increase. Despite this explosive topline growth, the micro-cap company with a market capitalisation of ₹107.00 crores continues to grapple with razor-thin profitability margins and structural challenges that have plagued its financial performance over the past five years.

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd has seen a marked shift in its valuation parameters, moving from fair to expensive territory, prompting a downgrade in its investment grade. With a price-to-earnings (P/E) ratio soaring to 200.86 and price-to-book value (P/BV) at 3.33, investors are urged to reassess the stock’s price attractiveness amid sector peers and historical benchmarks.

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating, driven primarily by a steep rise in its price-to-earnings (P/E) ratio and price-to-book value (P/BV). This change comes amid a mixed performance in the pharmaceuticals sector and raises questions about the stock’s price attractiveness relative to its peers and historical benchmarks.

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.